← Back
Capricor Therapeutics
CAPR · listed on Nasdaq · worth $385.46 million
$6.63
+6.42% on Oct 29
No insider bought Capricor Therapeutics stock in the last year. They sold it 6 times, $1.52 million in all.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
45.5M shares
78% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders sold Capricor Therapeutics stock and none bought. None of the 6 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Karen Krasney, EVP, GENERAL COUNSEL.
Big investors
People and funds that reported owning 5% or more of Capricor Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateMillennium Management LLC2.9%Oct 14Reported stake, oldest first: 4.9% (Aug 19) → 5.1% (Sep 14) → 2.9% (Oct 14)
Filed by someone who owns 5% or more and does not plan to influence the company.Millennium Management LLC5.1%Sep 14
Filed by someone who owns 5% or more and does not plan to influence the company.Millennium Management LLC4.9%Aug 19
Filed by someone who owns 5% or more and does not plan to influence the company.State Street5.9%Aug 7
Filed by someone who owns 5% or more and does not plan to influence the company.RA Capital Management5.2%Aug 3
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Capricor Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
1 more with Pro →Analysts, earnings and news
Analysts' price target
$27.00 average
5 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 3 quarters above
Q2 '26−$0.70 a share−$0.12
Q4 '25−$0.62 a share−$0.07
Q3 '25−$0.54 a share+$0.00